Floatz logo

Actinium Ac 225-Dota-Daratumumab

Recurrent Plasma Cell Myeloma

City of Hope Medical CenterunclassifiedPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

497 Active assets in the Recurrent Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

Actinium Ac 225-Dota-Daratumumab is also rated in:

myelodysplastic syndromeDormant
C
Indicative ·
39 / 100
View asset →
acute lymphoblastic leukemiaDormant
C
Indicative ·
37 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →